3-碘-4-异丙基苯甲酸 | 99059-64-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 3-碘-4-异丙基苯甲酸
• 英文名称: 3-iodo-4-isopropylbenzoic acid
• 英文别名: 3-iodo-4-propan-2-ylbenzoic acid
• CAS: 99059-64-0
• 化学式: C₁₀H₁₁IO₂
• 分子量: 290.101
• InChiKey: YKYRHJJXCOILPA-UHFFFAOYSA-N

物化性质

• 沸点：
  346.7±42.0 °C(Predicted)
• 密度：
  1.666±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-碘-4-异丙基苯甲酸 在 copper(l) iodide 、 四(三苯基膦)钯 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 、 cesium fluoride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 8.33h， 生成 4-isopropyl-3-(isoquinolin-4-ylethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
  参考文献：
  名称：

  Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors

  摘要：

  FGF receptors (FGFRs) are tyrosine kinases that are overexpressed in diverse tumors by genetic alterations such as gene amplifications, somatic mutations and translocations. Owing to this characteristic, FGFRs are attractive targets for cancer treatment. It has been demonstrated that most multi-targeted, ATP competitive tyrosine kinase inhibitors are active against FGFRs as well as other kinases. The design of new and more selective inhibitors of FGFRs, which might be reduced off-target and side effects, is a difficult yet significant challenge. The results of the current investigation, show that novel Ponatinib analogues are highly active as FGFR inhibitors and that they possess reduced kinase insert domain receptor (KDR) activities. Observations made in a structure and activity relationship (SAR) investigation led to the development of a promising, orally available lead compound 4, which displays a 50-100 fold in vitro selectivity for inhibition of FGFR1-3 over KDR. In addition, biological evaluation of compound 4 showed that it displays significant antitumor activities in FGFR1-amplificated H1581 and FGFR2amplificated SNU-16 xenograft models. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.10.003
• 作为产物：
  描述：

  4-异丙基苯甲酸 在 sodium periodate 、 lithium hydroxide monohydrate 、 硫酸 、 碘 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙酸酐 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-碘-4-异丙基苯甲酸
  参考文献：
  名称：

  Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on ano-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders

  摘要：

  Colony-stimulating factor 1 receptor (CSF-1R) is involved in inflammatory disorders as well as in many types of cancer. Based on high-throughput screening and docking results, we performed a detailed structure-activity-relationship study, leading to the discovery of a new series of compounds with nanomolar IC50 values against CSF-1R without the inhibition of fibroblast growth factor receptors. One of the most promising hits, compound 29, potently inhibited CSF-1R kinase with an IC50 value of 0.7 nM, while it showed no inhibition to the same family member FMS-like tyrosine kinase 3. Compound 29 displayed excellent anti-inflammatory effects against RAW264.7 macrophages indicated by significant inhibition against the activation of the CSF-1R pathway with low cytotoxicity. In addition, compound 29 exhibited strong in vivo anti-inflammatory efficacy alongside favorable drug characteristics. This novel compound 29 may serve as a new drug candidate with promising applications in inflammatory disorders.

  DOI：

  10.1021/acs.jmedchem.9b01912

文献信息

• PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Carter Percy H.

  公开号：US20070208056A1

  公开（公告）日：2007-09-06

  The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.

  本申请描述了MIP-1α或CCR-1的取代哌啶调节剂或其立体异构体或药学上可接受的盐。此外，还公开了使用上述调节剂治疗和预防炎症性疾病，如哮喘和过敏性疾病，以及自身免疫病理学，如类风湿性关节炎和移植排斥等方法。
• Piperidinyl derivatives as modulators of chemokine receptor activity
  申请人：Bristol-Myers Squibb Company

  公开号：US07985861B2

  公开（公告）日：2011-07-26

  The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.

  本申请描述了替代的哌啶基MIP-1α或CCR-1调节剂或其立体异构体或药学上可接受的盐。此外，还揭示了使用所述调节剂治疗和预防哮喘和过敏性疾病以及自身免疫病理学，如类风湿性关节炎和移植排斥等炎症性疾病的方法。
• Everitt et al., Journal of the Chemical Society, 1956, p. 2286,2289
  作者：Everitt et al.

  DOI：——

  日期：——
• US7601844B2
  申请人：——

  公开号：US7601844B2

  公开（公告）日：2009-10-13
• US7985861B2
  申请人：——

  公开号：US7985861B2

  公开（公告）日：2011-07-26